Bavarian Nordic (OTCMKTS:BVNRY) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Bavarian Nordic shares crossed below their 200-day moving average of $10.20 (trading as low as $9.77 and last at $9.8050), a bearish technical signal as the stock fell about 0.6% on light volume.
• The vaccine maker (Jynneos/Imvamune/Imvanex, Rabipur, Encepur) has a $2.33B market cap and P/E of 11.14; it reported a ($0.20) EPS on $226.16M revenue last quarter but showed a 22.2% net margin and 11.27% return on equity.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $10.20 and traded as low as $9.77. Bavarian Nordic shares last traded at $9.8050, with a volume of 918 shares traded.

Bavarian Nordic Stock Down 0.6%

The stock has a market cap of $2.33 billion, a P/E ratio of 11.14 and a beta of 1.21. The business has a 50 day moving average price of $9.90 and a two-hundred day moving average price of $10.20.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $226.16 million during the quarter. Bavarian Nordic had a return on equity of 11.27% and a net margin of 22.20%.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic's operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company's commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.